Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuT cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsCARs in chronic lymphocytic leukemia -- ready to driveProgress and prospects for engineered T cell therapiesGenetically modified T cells for the treatment of malignant diseaseTowards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infectionClinical application of adoptive T cell therapy in solid tumorsChimeric antigen receptor therapy for cancerRegulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluationChimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trialsT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesToxicity and management in CAR T-cell therapyT cell engineering as therapy for cancer and HIV: our synthetic futureTherapeutic genome editing: prospects and challengesEngineered T cells for cancer treatmentStrategies to genetically engineer T cells for cancer immunotherapy.The future is now: chimeric antigen receptors as new targeted therapies for childhood cancerA universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.CAR-modified T-cell therapy for cancer: an updated review.In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)Immunotherapy for metastatic solid cancersChimeric antigen receptors for T cell immunotherapy: current understanding and future directionsTargeted immunotherapy of cancer with CAR T cells: achievements and challenges.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptorsClinical application of genetically modified T cells in cancer therapy.Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.Treating cancer with genetically engineered T cells.T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo.Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive SarcomaAntitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastomaTargeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cellsNovel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor ActivityRedirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptorRapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis.CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene
P2860
Q21131200-792C06E1-5DA5-4DFE-9CBC-E16A2566FBACQ24632975-5CB7697B-3075-464A-8EA5-2183735713A0Q26753082-A92C7949-7147-4A25-9D79-596D819CC468Q26830526-A5CF19EB-E107-406E-B493-22CFDAD75D3BQ26852923-6A776002-379F-4D92-82A7-0C51F0C9318BQ26860657-4989C7E1-AA6D-4166-81E7-2FC5B21C3300Q27005830-6F02B919-26BE-4A5B-93D6-D6743CD2ADF8Q27011283-E0F25D0B-2949-43E0-81EC-F5CB891EFB18Q27013599-0EF8EDB3-6936-4408-B93D-B99E652DFAA5Q27027876-669B4DCE-9BBC-41A0-9A1D-AD88BF3EA990Q27312288-E46A4356-C198-47FB-BED4-E3870857A80BQ28074619-A879BE71-066A-427F-A8E7-80C283B4F75EQ28075314-7E494C9C-FD2A-4CE6-9EF6-8F89FE58A71CQ28082253-AD0D182D-A439-4F53-A1FF-6DD4FFD3EBD5Q28087380-4952A5C7-9CC5-4A98-82BB-6DF74DB80ECDQ33578792-6460CF9F-A35A-4FC0-B115-983152830358Q33655849-EAE534C6-63DB-4073-9843-BF4D67280C46Q33993529-22077D0B-B133-40E5-BF39-8CDFD528D7E9Q34030602-96A1BFE8-AF53-4328-BFCC-7E94E142F7D7Q34044213-DC4AB469-86F5-47E8-AE02-F8F5BE4C832AQ34073529-A45D53DE-0B0E-45F8-9B06-708565BAD12EQ34219970-54619953-815C-4487-A6D5-470687A00CF6Q34248531-8DE3BC8E-3AD5-4B6A-97C9-76F01EA13194Q34270375-C60FC220-7F9F-4B78-B5A9-C5176D3D94ECQ34309388-4A2C50CD-4221-41A1-A5B3-1B7943B99583Q34511646-8879AC44-BCD1-4B9F-AED9-2673292B219FQ34520155-3AEDD7B2-4B9A-48D5-9BE2-FD5B79FA443AQ34592273-89CBBEC9-8E3F-4EE9-AF22-34B1D15E1BC4Q34729692-744E80AD-7713-41A6-803F-4C7F618C3350Q35353365-7AAF1F2E-DA0A-4AEC-A2A6-78EDFBF378CBQ35483599-950D9E02-F95C-44F6-A0E9-EE044F1A2828Q35598804-0B1B09C0-AB64-4B31-84B7-BF3181117B0AQ35604043-B6D3D2DC-0B54-4297-8CD6-AE5D0C2A2674Q35661999-053118E4-733E-4ED0-82E8-6C858000FD1CQ35745453-B94D2DE8-6B9C-4DD1-B018-F5AD35FA896CQ35802193-4034E00F-ADF2-4D77-B276-97E88D30AB3EQ35917978-95907CAC-698D-4CB0-AD1F-83E7AF469701Q35953372-016B4A79-7D8C-44AE-A4E4-62D9208FA653Q35986612-E7E22C2C-64DD-40F8-98B1-A0F3F452E612Q36242630-2DF1DE72-3A5B-4586-913D-9207AF9FB3C7
P2860
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immune responses to transgene ...... th ex vivo-engineered T cells.
@ast
Immune responses to transgene ...... th ex vivo-engineered T cells.
@en
type
label
Immune responses to transgene ...... th ex vivo-engineered T cells.
@ast
Immune responses to transgene ...... th ex vivo-engineered T cells.
@en
prefLabel
Immune responses to transgene ...... th ex vivo-engineered T cells.
@ast
Immune responses to transgene ...... th ex vivo-engineered T cells.
@en
P2093
P1433
P1476
Immune responses to transgene ...... th ex vivo-engineered T cells.
@en
P2093
Cor H J Lamers
Egbert Oosterwijk
Jan W Gratama
Jeannette Oosterwijk-Wakka
Marieke Broertjes
Pascal van Elzakker
Ralph Willemsen
Reno Debets
Sabine van Steenbergen-Langeveld
Stefan Sleijfer
P356
10.1182/BLOOD-2010-07-294520
P407
P577
2010-10-01T00:00:00Z